| Name | Title | Contact Details |
|---|
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks, and labs in more than 120 countries, Ortho`s high-quality products and services enable healthcare professionals to make better-informed treatment decisions. For the immunohematology community, Ortho`s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management, and interpretation tools to clinical laboratories around the world to help them run more efficiently, effectively and improve patient care. Ortho`s purpose is to improve and save lives with diagnostics and it does that by reimagining what`s possible. This is what has defined Ortho for more than 75 years, and it`s what drives Ortho forward.
Westline Medical Management is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Angel Canada Enterprises Ltd. is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fillauer is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.